Mary Beth Rios

10.2k total citations
129 papers, 7.4k citations indexed

About

Mary Beth Rios is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Mary Beth Rios has authored 129 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Hematology, 100 papers in Genetics and 72 papers in Rheumatology. Recurrent topics in Mary Beth Rios's work include Chronic Myeloid Leukemia Treatments (108 papers), Chronic Lymphocytic Leukemia Research (96 papers) and Eosinophilic Disorders and Syndromes (72 papers). Mary Beth Rios is often cited by papers focused on Chronic Myeloid Leukemia Treatments (108 papers), Chronic Lymphocytic Leukemia Research (96 papers) and Eosinophilic Disorders and Syndromes (72 papers). Mary Beth Rios collaborates with scholars based in United States, France and Germany. Mary Beth Rios's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Stefan Faderl, Guillermo Garcia‐Manero, Jianqin Shan, Srđan Verstovšek and Deborah A. Thomas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mary Beth Rios

128 papers receiving 7.2k citations

Peers

Mary Beth Rios
Jianqin Shan United States
Susan O’Brien United States
Philipp le Coutre Germany
Stephen G. O’Brien United Kingdom
Laurence Legros France
Nicoletta Testoni Italy
H. Kantarjian United States
Haifa Kathrin Al‐Ali Germany
Zbigniew Rudzki Australia
Elisabetta Abruzzese Italy
Jianqin Shan United States
Mary Beth Rios
Citations per year, relative to Mary Beth Rios Mary Beth Rios (= 1×) peers Jianqin Shan

Countries citing papers authored by Mary Beth Rios

Since Specialization
Citations

This map shows the geographic impact of Mary Beth Rios's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Beth Rios with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Beth Rios more than expected).

Fields of papers citing papers by Mary Beth Rios

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Beth Rios. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Beth Rios. The network helps show where Mary Beth Rios may publish in the future.

Co-authorship network of co-authors of Mary Beth Rios

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Beth Rios. A scholar is included among the top collaborators of Mary Beth Rios based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Beth Rios. Mary Beth Rios is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alfayez, Mansour, Hagop M. Kantarjian, Tapan M. Kadia, et al.. (2018). Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience. Blood. 132(Supplement 1). 5447–5447. 1 indexed citations
2.
Sasaki, Koji, Hagop M. Kantarjian, Susan O’Brien, et al.. (2017). Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 124(6). 1160–1168. 23 indexed citations
3.
Kantarjian, Hagop M., Deborah A. Thomas, Jeffrey L. Jorgensen, et al.. (2012). Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The Lancet Oncology. 13(4). 403–411. 309 indexed citations
4.
Kantarjian, Hagop M., Susan O’Brien, Jianqin Shan, et al.. (2007). Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer. 112(4). 837–845. 82 indexed citations
5.
Jabbour, Elias, Hagop M. Kantarjian, Dan Jones, et al.. (2006). Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 20(10). 1767–1773. 310 indexed citations
6.
Kantarjian, Hagop M., Moshe Talpaz, Susan O’Brien, et al.. (2005). Significance of myelofibrosis in early chronic‐phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer. 104(4). 777–780. 11 indexed citations
7.
8.
9.
10.
Kantarjian, Hagop M., Moshe Talpaz, Susan O’Brien, et al.. (2003). The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 100(1). 116–121. 93 indexed citations
11.
Ault, Patricia, et al.. (2003). Management of Molecular‐Targeted Therapy for Chronic Myelogenous Leukemia. Journal of the American Academy of Nurse Practitioners. 15(7). 292–296. 5 indexed citations
12.
Onida, Francesco, Greg Ball, Hagop M. Kantarjian, et al.. (2002). Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 95(8). 1673–1684. 65 indexed citations
13.
Joly, Florence, Jean‐François Héron, Pierre Kerbrat, et al.. (2000). High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecologic Oncology. 78(3). 361–368. 18 indexed citations
14.
Kantarjian, H, Moshe Talpaz, Stephen J. O’Brien, et al.. (1999). Significance of FHIT expression in chronic myelogenous leukemia.. PubMed. 5(12). 4059–64. 9 indexed citations
15.
Sacchi, Stefano, Hagop M. Kantarjian, Susan O’Brien, et al.. (1999). Chronic myelogenous leukemia in nonlymphoid blastic phase. Cancer. 86(12). 2632–2641. 155 indexed citations
16.
Majlis, Alejandro, Terry L. Smith, Moshe Talpaz, et al.. (1996). Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.. Journal of Clinical Oncology. 14(1). 196–203. 63 indexed citations
17.
Kantarjian, Hagop M., Varsha Gandhi, Susan O’Brien, et al.. (1993). Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 72(7). 2155–2160. 43 indexed citations
18.
Estey, Elihu H., William Plunkett, Varsha Gandhi, et al.. (1993). Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia. Leukemia & lymphoma. 9(4-5). 343–350. 129 indexed citations
19.
Estey, Elihu H., William Plunkett, Hagop Kantarjian, Mary Beth Rios, & Michael J. Keating. (1993). Treatment of Relapsed or Refractory AML with Intermediate-dose Arabinosylcytosine (Ara-C): Confirmation of the Importance of Ara-C Triphosphate Formation in Mediating Response to Ara-C. Leukemia & lymphoma. 10(sup1). 115–121. 8 indexed citations
20.
Giralt, Sergio, Hagop M. Kantarjian, Moshe Talpaz, et al.. (1993). Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.. Journal of Clinical Oncology. 11(6). 1055–1061. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianqin Shan Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Philipp le Coutre Breakdown of academic impact, for papers by Stephen G. O’Brien Breakdown of academic impact, for papers by Laurence Legros Breakdown of academic impact, for papers by Nicoletta Testoni Breakdown of academic impact, for papers by H. Kantarjian Breakdown of academic impact, for papers by Haifa Kathrin Al‐Ali Breakdown of academic impact, for papers by Zbigniew Rudzki Breakdown of academic impact, for papers by Elisabetta Abruzzese
Rankless by CCL
2026